
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Vonoprazan–Tetracycline Dual Regimen as Rescue Therapy for Helicobacter pylori Infection: Randomized Controlled Trial</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>Vonoprazan–Tetracycline Dual Regimen as Rescue Therapy for Helicobacter pylori Infection: Randomized Controlled Trial</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Gastroenterology, Accepted 6 January 2026</li>
<li style="margin-left: 0px;">Topic: Helicobacter pylori Rescue Therapy</li>
<li style="margin-left: 0px;">Author(s): Gao W, Li J, Yang G, et al.</li>
</ul>
<details><summary><strong>1. Study Design and Methodology</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Trial Overview</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prospective, open-label, randomized controlled non-inferiority trial conducted at Peking University First Hospital (Beijing, China) from February 2024 to July 2025</li>
<li style="margin-left: 0px;">Registered at chictr.org.cn (ChiCTR2400080705)</li>
<li style="margin-left: 0px;">Compared vonoprazan-tetracycline (VT) dual therapy vs bismuth quadruple therapy (BQT) as rescue treatment</li>
<li style="margin-left: 0px;">350 patients randomized 1:1 (175 per group)</li>
</ul>
</div></details>
<details><summary><strong>Eligibility Criteria</strong></summary><div style="padding-left: 20px;">
<p><strong>Inclusion</strong>: Adults aged 18-80 years with confirmed H. pylori infection and ≥1 prior eradication failure</p>
<p><strong>Exclusion</strong>:</p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prior use of PPI+bismuth+tetracycline+metronidazole combination</li>
<li style="margin-left: 0px;">Antibiotics, bismuth, or PPI use within 4 weeks prior to enrollment</li>
<li style="margin-left: 0px;">Pregnancy/breastfeeding</li>
<li style="margin-left: 0px;">Severe comorbidities (advanced hepatic, cardiac, renal disease, malignancy, alcohol dependence)</li>
<li style="margin-left: 0px;">Known hypersensitivity to study medications</li>
<li style="margin-left: 0px;">Psychiatric conditions precluding cooperation</li>
</ul>
</div></details>
<details><summary><strong>Treatment Regimens</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>VT Dual Therapy</strong>: Vonoprazan 20 mg b.i.d. + Tetracycline 500 mg t.i.d. for 14 days</li>
<li style="margin-left: 0px;"><strong>BQT</strong>: Lansoprazole 30 mg b.i.d. + Colloidal bismuth 150 mg t.i.d. + Tetracycline 500 mg t.i.d. + Metronidazole 400 mg t.i.d. for 14 days</li>
</ul>
</div></details>
<details><summary><strong>Sample Size Calculation</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Non-inferiority margin: 10%</li>
<li style="margin-left: 0px;">Expected BQT eradication rate: 88% (based on prior rescue therapy data)</li>
<li style="margin-left: 0px;">Required sample: 166 per group → adjusted for 5% dropout to 175 per group</li>
<li style="margin-left: 0px;">Power: 80%, α = 0.025 (one-sided)</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>2. Patient Enrollment and Baseline Characteristics</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Disposition</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">382 individuals screened → 350 randomized (175 VT, 175 BQT)</li>
<li style="margin-left: 0px;">Follow-up completed July 2025</li>
<li style="margin-left: 0px;">Lost to follow-up: 5 VT, 6 BQT (excluded from mITT)</li>
<li style="margin-left: 0px;">Discontinued treatment (&lt;80% adherence): 2 VT, 16 BQT</li>
<li style="margin-left: 0px;">PP population: 168 VT, 153 BQT</li>
</ul>
</div></details>
<details><summary><strong>Baseline Demographics (Table 1)</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Characteristic</th>
<th>VT Group (n=175)</th>
<th>BQT Group (n=175)</th>
<th>P value</th>
</tr></thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>48 (13.4) years</td>
<td>45.7 (12.1) years</td>
<td>0.10</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>60/115</td>
<td>66/109</td>
<td>0.58</td>
</tr>
<tr>
<td>Body weight, mean (SD)</td>
<td>63.5 (12.4) kg</td>
<td>63.3 (11.2) kg</td>
<td>0.90</td>
</tr>
<tr>
<td>BMI, mean (SD)</td>
<td>23 (3.5) kg/m²</td>
<td>23 (3) kg/m²</td>
<td>0.89</td>
</tr>
<tr>
<td>Cigarette smoking</td>
<td>15 (8.6%)</td>
<td>9 (5.1%)</td>
<td>0.29</td>
</tr>
<tr>
<td>Alcohol drinking</td>
<td>30 (17.1%)</td>
<td>31 (17.7%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Family history of gastric cancer</td>
<td>17 (9.7%)</td>
<td>20 (11.4%)</td>
<td>0.73</td>
</tr>
<tr>
<td>Penicillin allergy</td>
<td>63 (36%)</td>
<td>56 (32%)</td>
<td>0.50</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>Prior Treatment History (Table 2)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Median prior failures: 2 (IQR 1-3) for VT, 2 (IQR 1-2) for BQT</li>
<li style="margin-left: 0px;">Previous regimens included: clarithromycin-based (89.1% VT, 92.0% BQT), levofloxacin-based (38.9% VT, 44.6% BQT), metronidazole-based (54.3% VT, 45.1% BQT)</li>
<li style="margin-left: 0px;">Amoxicillin-containing regimen failures: ~70% of patients</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Primary Efficacy Outcomes — Eradication Rates</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Intention-to-Treat (ITT) Analysis</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT: <strong>88.0%</strong> (154/175; 95% CI: 82.0–92.2%)</li>
<li style="margin-left: 0px;">BQT: <strong>86.3%</strong> (151/175; 95% CI: 80.1–90.8%)</li>
<li style="margin-left: 0px;">Difference: <strong>+1.7%</strong> (95% CI: –5.9% to 9.3%)</li>
<li style="margin-left: 0px;">P for difference = 0.75</li>
<li style="margin-left: 0px;"><strong>P for non-inferiority = 0.0005</strong> ✓</li>
</ul>
</div></details>
<details><summary><strong>Modified Intention-to-Treat (mITT) Analysis</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT: <strong>90.6%</strong> (154/170; 95% CI: 84.9–94.4%)</li>
<li style="margin-left: 0px;">BQT: <strong>89.3%</strong> (151/169; 95% CI: 83.5–93.4%)</li>
<li style="margin-left: 0px;">Difference: <strong>+1.2%</strong> (95% CI: –5.7% to 8.2%)</li>
<li style="margin-left: 0px;">P for difference = 0.84</li>
<li style="margin-left: 0px;"><strong>P for non-inferiority = 0.0003</strong> ✓</li>
</ul>
</div></details>
<details><summary><strong>Per-Protocol (PP) Analysis</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT: <strong>91.1%</strong> (153/168; 95% CI: 85.4–94.7%)</li>
<li style="margin-left: 0px;">BQT: <strong>92.2%</strong> (141/153; 95% CI: 86.4–95.7%)</li>
<li style="margin-left: 0px;">Difference: <strong>–1.1%</strong> (95% CI: –7.8% to 5.6%)</li>
<li style="margin-left: 0px;">P for difference = 0.88</li>
<li style="margin-left: 0px;"><strong>P for non-inferiority = 0.002</strong> ✓</li>
</ul>
</div></details>
<details><summary><strong>Subgroup Analysis by Penicillin Allergy (mITT)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT without penicillin allergy: 91.8% (101/110)</li>
<li style="margin-left: 0px;">VT with penicillin allergy: 88.3% (53/60)</li>
<li style="margin-left: 0px;">BQT without penicillin allergy: 89.4% (101/113)</li>
<li style="margin-left: 0px;">BQT with penicillin allergy: 89.3% (50/56)</li>
<li style="margin-left: 0px;">No significant difference between allergy subgroups in either group</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Safety Profile — Treatment-Emergent Adverse Events (TEAEs)</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Overall Incidence</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT group: <strong>10.9%</strong> (19/175)</li>
<li style="margin-left: 0px;">BQT group: <strong>45.7%</strong> (80/175)</li>
<li style="margin-left: 0px;"><strong>P &lt; 0.001</strong> — significantly lower with VT dual therapy</li>
</ul>
</div></details>
<details><summary><strong>Adverse Event Severity Grading</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Severity</th>
<th>VT Group</th>
<th>BQT Group</th>
<th>P value</th>
</tr></thead>
<tbody>
<tr>
<td>Mild</td>
<td>13 (7.4%)</td>
<td>54 (30.9%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Moderate</td>
<td>4 (2.3%)</td>
<td>10 (5.7%)</td>
<td>0.17</td>
</tr>
<tr>
<td>Severe</td>
<td>2 (1.1%)</td>
<td>16 (9.1%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Moderate-to-severe combined</td>
<td>6 (3.4%)</td>
<td>26 (14.9%)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>Specific Adverse Events by Type</strong></summary><div style="padding-left: 20px;">
<p><strong>Most Common in VT Group:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Constipation: 5 cases (2.9%)</li>
<li style="margin-left: 0px;">Abdominal distension: 3 cases (1.7%)</li>
<li style="margin-left: 0px;">Nausea: 3 cases (1.7%)</li>
<li style="margin-left: 0px;">Abdominal pain: 2 cases (1.1%)</li>
<li style="margin-left: 0px;">Dizziness: 2 cases (1.1%)</li>
</ul>
<p><strong>Most Common in BQT Group:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Nausea: 37 cases (21.1%)</li>
<li style="margin-left: 0px;">Diarrhea: 12 cases (6.9%)</li>
<li style="margin-left: 0px;">Abdominal pain: 9 cases (5.1%)</li>
<li style="margin-left: 0px;">Bitter taste: 8 cases (4.6%)</li>
<li style="margin-left: 0px;">Constipation: 7 cases (4.0%)</li>
</ul>
</div></details>
<details><summary><strong>Treatment Discontinuation Due to AEs</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT group: <strong>0.0%</strong> (0/175)</li>
<li style="margin-left: 0px;">BQT group: <strong>8.6%</strong> (15/175)</li>
<li style="margin-left: 0px;"><strong>P &lt; 0.001</strong></li>
</ul>
</div></details>
<details><summary><strong>Discontinuation Details (BQT Group, Table 3)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">15 patients discontinued due to TEAEs</li>
<li style="margin-left: 0px;">Most common reasons: nausea, vomiting, diarrhea, fever</li>
<li style="margin-left: 0px;">Duration of treatment before discontinuation ranged from 1-11 days</li>
<li style="margin-left: 0px;">Only 6/15 (40%) achieved successful eradication despite early discontinuation</li>
</ul>
</div></details>
<details><summary><strong>Discontinuation Details (VT Group)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">2 patients discontinued treatment:</li>
<li style="margin-left: 20px;">Patient 120: Stopped on day 7 due to travel (not TEAE-related) → eradication failure</li>
<li style="margin-left: 20px;">Patient 049: Stopped on day 11 due to viral infection with fever after alcohol consumption → eradication success</li>
</ul>
</div></details>
<details><summary><strong>Serious Outcomes</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">No hospitalizations in either group</li>
<li style="margin-left: 0px;">No deaths in either group</li>
<li style="margin-left: 0px;">All adverse events resolved without intervention after treatment cessation</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5. Treatment Adherence</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Overall Adherence Rates</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Defined as intake of ≥80% of prescribed doses</li>
<li style="margin-left: 0px;">VT group: <strong>96.0%</strong> (168/175)</li>
<li style="margin-left: 0px;">BQT group: <strong>87.4%</strong> (153/175)</li>
<li style="margin-left: 0px;"><strong>P = 0.006</strong></li>
</ul>
</div></details>
<details><summary><strong>Adherence by AE Severity</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>AE Grade</th>
<th>VT Group</th>
<th>BQT Group</th>
</tr></thead>
<tbody>
<tr>
<td>Mild</td>
<td>13/13 (100%)</td>
<td>54/54 (100%)</td>
</tr>
<tr>
<td>Moderate</td>
<td>4/4 (100%)</td>
<td>10/10 (100%)</td>
</tr>
<tr>
<td>Severe</td>
<td>2/2 (100%)</td>
<td>4/16 (25%)</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>Factors Contributing to Higher Adherence in VT Group</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Simplified dual regimen vs. quadruple therapy</li>
<li style="margin-left: 0px;">Fewer pills required (vonoprazan 20 mg b.i.d. + tetracycline 500 mg t.i.d.)</li>
<li style="margin-left: 0px;">Lower pill burden compared to BQT (4 drugs vs. 2 drugs)</li>
<li style="margin-left: 0px;">Fewer adverse events leading to treatment completion</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6. Discussion — Key Findings and Clinical Implications</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Primary Efficacy Finding</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT dual therapy achieved non-inferior eradication rates compared to BQT across all analysis populations (ITT, mITT, PP)</li>
<li style="margin-left: 0px;">Eradication rates: 90.6% VT vs 89.3% BQT (mITT)</li>
<li style="margin-left: 0px;">Non-inferiority P = 0.0003 (threshold: P &lt; 0.01)</li>
<li style="margin-left: 0px;">First prospective evaluation of vonoprazan-tetracycline as penicillin-free rescue regimen</li>
</ul>
</div></details>
<details><summary><strong>Mechanistic Rationale for VT Dual Therapy</strong></summary><div style="padding-left: 20px;">
<p><strong>Acid Suppression:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Success of H. pylori eradication depends on intensity, consistency, and duration of acid suppression</li>
<li style="margin-left: 0px;">Vonoprazan (P-CAB) provides potent acid suppression maintaining gastric pH ≥6</li>
<li style="margin-left: 0px;">Superior acid suppression vs. PPIs enables single antibiotic to achieve reliable eradication</li>
</ul>
<p><strong>Antibiotic Selection:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Tetracycline resistance rate: typically &lt;3% globally</li>
<li style="margin-left: 0px;">Low primary resistance maintained even after prior treatment failures</li>
<li style="margin-left: 0px;">Stable resistance profile in Asia-Pacific region (1990-2022): ~4% tetracycline resistance</li>
<li style="margin-left: 0px;">Compares favorably to high metronidazole (52%), levofloxacin (26%), and clarithromycin (22%) resistance rates</li>
</ul>
</div></details>
<details><summary><strong>Comparison with Prior Studies</strong></summary><div style="padding-left: 20px;">
<p><strong>First-line Setting:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prior RCT in penicillin-allergic patients: VT dual therapy achieved 94.5% eradication (mITT)</li>
<li style="margin-left: 0px;">Comparable to BQT with significantly fewer AEs (14.0% vs 48.0%)</li>
</ul>
<p><strong>Rescue Setting:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prior retrospective study: VT achieved 90.9% (40/44) eradication rate</li>
<li style="margin-left: 0px;">Current RCT confirms similar efficacy: 90.6% (mITT)</li>
</ul>
</div></details>
<details><summary><strong>Advantages of VT Dual Therapy Over BQT</strong></summary><div style="padding-left: 20px;">
<p><strong>Efficacy:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Non-inferior eradication rates</li>
</ul>
<p><strong>Safety:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Significantly lower TEAE incidence: 10.9% vs 45.7% (P &lt; 0.001)</li>
<li style="margin-left: 0px;">Fewer severe AEs: 1.1% vs 9.1% (P = 0.001)</li>
<li style="margin-left: 0px;">No treatment discontinuations due to AEs vs 8.6% in BQT</li>
</ul>
<p><strong>Adherence:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Higher completion rates: 96.0% vs 87.4% (P = 0.006)</li>
<li style="margin-left: 0px;">Simplified regimen (2 drugs vs 4 drugs)</li>
</ul>
<p><strong>Microbiome Impact:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Standard-dose tetracycline (1.5 g/day) vs higher doses in some regimens</li>
<li style="margin-left: 0px;">Avoids bismuth and additional antibiotics in BQT</li>
<li style="margin-left: 0px;">Potential for less gut microbiota disruption</li>
</ul>
</div></details>
<details><summary><strong>Clinical Positioning of VT Dual Therapy</strong></summary><div style="padding-left: 20px;">
<p><strong>Suitable Patient Populations:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Patients with prior eradication failure (rescue setting)</li>
<li style="margin-left: 0px;">Patients with penicillin allergy or amoxicillin ineligibility</li>
<li style="margin-left: 0px;">Patients who failed amoxicillin-containing regimens (~70% of enrolled patients)</li>
<li style="margin-left: 0px;">Patients requiring simplified treatment regimens</li>
</ul>
<p><strong>Complementary to High-Dose Amoxicillin Dual Therapy:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">No cross-resistance between tetracycline and amoxicillin</li>
<li style="margin-left: 0px;">VT serves as alternative when amoxicillin-based regimens fail</li>
</ul>
</div></details>
<details><summary><strong>Treatment Optimization Strategy</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Reflects trend toward &quot;subtraction&quot; in H. pylori therapy</li>
<li style="margin-left: 0px;">Focus on effective acid suppression + low-resistance antibiotic</li>
<li style="margin-left: 0px;">Achieves high eradication with simplified regimen (2 drugs vs 4)</li>
<li style="margin-left: 0px;">Maintains therapeutic effectiveness without increasing antibiotic doses</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>7. Study Limitations</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Generalizability</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Initially designed as multicenter trial but completed at single center (Peking University First Hospital)</li>
<li style="margin-left: 0px;">All participants from one tertiary hospital in China</li>
<li style="margin-left: 0px;">Not yet evaluated outside China</li>
<li style="margin-left: 0px;">Regional differences may affect results:</li>
<li style="margin-left: 20px;">Acid-inhibitor potency variations</li>
<li style="margin-left: 20px;">Body weight distribution differences</li>
<li style="margin-left: 20px;">Antibiotic pharmacokinetics</li>
</ul>
</div></details>
<details><summary><strong>Antibiotic Resistance Testing</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Not performed at individual patient level</li>
<li style="margin-left: 0px;">Relied on existing surveillance data showing tetracycline resistance &lt;4% in China</li>
<li style="margin-left: 0px;">Cannot directly correlate eradication outcomes with resistance profiles</li>
</ul>
</div></details>
<details><summary><strong>Open-Label Design</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Potential reporting bias in adverse event assessment</li>
<li style="margin-left: 0px;">Unequal pill burden (VT: fewer pills vs BQT) may contribute to bias</li>
<li style="margin-left: 0px;">Patients taking fewer medications might perceive treatment as easier and underreport mild AEs</li>
</ul>
</div></details>
<details><summary><strong>Non-Inferiority Margin</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">10% margin may be considered relatively wide</li>
<li style="margin-left: 0px;">Future trials with narrower margins and larger samples needed</li>
</ul>
</div></details>
<details><summary><strong>Subgroup Analysis Limitations</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Sample size not planned for stratified analysis by number of prior failures</li>
<li style="margin-left: 0px;">Cannot provide reliable eradication estimates for single vs. multiple (≥2) prior failures</li>
<li style="margin-left: 0px;">Small number of patients with ≥2 prior failures</li>
<li style="margin-left: 0px;">Heterogeneous previous regimens in heavily pretreated patients</li>
</ul>
</div></details>
<details><summary><strong>Microbiome Assessment</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">No gut microbiota profiling before/after treatment</li>
<li style="margin-left: 0px;">Cannot assess ecological impact of simplified dual regimen</li>
</ul>
</div></details>
<details><summary><strong>Future Research Needs</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Multicenter, multinational trials</li>
<li style="margin-left: 0px;">Blinded designs with matched placebo tablets</li>
<li style="margin-left: 0px;">Antibiotic resistance assessment at individual level</li>
<li style="margin-left: 0px;">Microbiome profiling studies</li>
<li style="margin-left: 0px;">Evaluation in diverse populations with varying body weight distributions</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Conclusion</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Main Findings</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Fourteen-day vonoprazan-tetracycline dual therapy demonstrated <strong>non-inferior eradication rates</strong> compared to standard bismuth quadruple therapy as rescue treatment for H. pylori infection</li>
<li style="margin-left: 0px;">VT achieved 90.6% eradication rate (mITT) vs 89.3% for BQT</li>
<li style="margin-left: 0px;">Non-inferiority established with P = 0.0003 (threshold: P &lt; 0.01)</li>
</ul>
</div></details>
<details><summary><strong>Efficacy Summary</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">ITT analysis: 88.0% VT vs 86.3% BQT (P for non-inferiority = 0.0005)</li>
<li style="margin-left: 0px;">mITT analysis: 90.6% VT vs 89.3% BQT (P for non-inferiority = 0.0003)</li>
<li style="margin-left: 0px;">PP analysis: 91.1% VT vs 92.2% BQT (P for non-inferiority = 0.002)</li>
<li style="margin-left: 0px;">No significant difference between groups in any analysis population (P &gt; 0.05)</li>
</ul>
</div></details>
<details><summary><strong>Safety and Tolerability</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Significantly lower adverse event rate: <strong>10.9% VT vs 45.7% BQT</strong> (P &lt; 0.001)</li>
<li style="margin-left: 0px;">Fewer severe adverse events: <strong>1.1% VT vs 9.1% BQT</strong> (P = 0.001)</li>
<li style="margin-left: 0px;">No treatment discontinuations due to AEs in VT group vs 8.6% in BQT (P &lt; 0.001)</li>
<li style="margin-left: 0px;">All adverse events resolved without intervention after treatment completion</li>
</ul>
</div></details>
<details><summary><strong>Adherence</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Higher treatment adherence: <strong>96.0% VT vs 87.4% BQT</strong> (P = 0.006)</li>
<li style="margin-left: 0px;">Simplified dual regimen improved patient compliance</li>
</ul>
</div></details>
<details><summary><strong>Clinical Value</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">First prospective evidence for VT as effective rescue therapy</li>
<li style="margin-left: 0px;">Penicillin-free composition suitable for patients with penicillin allergy</li>
<li style="margin-left: 0px;">Viable alternative for patients who failed amoxicillin-containing regimens (~70% of study population)</li>
<li style="margin-left: 0px;">Simplified regimen (2 drugs) offers practical advantage over quadruple therapy (4 drugs)</li>
</ul>
</div></details>
<details><summary><strong>Population-Specific Findings</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Effective in patients with and without penicillin allergy</li>
<li style="margin-left: 0px;">Consistent efficacy regardless of number of prior treatment failures</li>
<li style="margin-left: 0px;">Comparable eradication rates to BQT across all subgroups</li>
</ul>
</div></details>
<details><summary><strong>Final Statement</strong></summary><div style="padding-left: 20px;">
<p>This randomized controlled trial provides evidence that vonoprazan-tetracycline dual therapy is an <strong>effective and well-tolerated rescue regimen</strong> for H. pylori infection in Chinese patients with prior eradication failure. The simplified regimen achieves eradication rates non-inferior to standard bismuth quadruple therapy while substantially reducing adverse events and improving adherence. By omitting bismuth and one additional antibiotic without compromising efficacy, this optimized dual therapy offers a practical alternative for rescue treatment, particularly for patients with penicillin allergy or prior failure of amoxicillin-containing regimens.</p>
</div></details>
</div></details>
<details><summary><strong>9. Clinical Take-Home Points — What You Need to Know</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Background and Context</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Rescue therapy for H. pylori typically relies on multi-drug quadruple regimens (PPI + bismuth + tetracycline + metronidazole)</li>
<li style="margin-left: 0px;">Quadruple regimens can be difficult for patients to tolerate and complete due to high pill burden and adverse events</li>
<li style="margin-left: 0px;">The authors previously demonstrated that simplified vonoprazan-tetracycline (VT) dual therapy was effective as first-line treatment</li>
<li style="margin-left: 0px;">This study examines whether VT remains effective after previous eradication failure</li>
</ul>
</div></details>
<details><summary><strong>New Findings from This Trial</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>First prospective evaluation</strong> of VT dual therapy as rescue option</li>
<li style="margin-left: 0px;">Non-inferior eradication rates compared to bismuth quadruple therapy:</li>
<li style="margin-left: 20px;">mITT: 90.6% VT vs 89.3% BQT (P for non-inferiority = 0.0003)</li>
<li style="margin-left: 0px;">Markedly fewer adverse events: <strong>10.9% VT vs 45.7% BQT</strong> (P &lt; 0.001)</li>
<li style="margin-left: 0px;">Better overall tolerability and adherence: <strong>96.0% VT vs 87.4% BQT</strong> (P = 0.006)</li>
<li style="margin-left: 0px;">No treatment discontinuations due to AEs in VT group</li>
</ul>
</div></details>
<details><summary><strong>Limitations to Consider</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Open-label, single-center design conducted in China</li>
<li style="margin-left: 0px;">Did not include antibiotic resistance testing</li>
<li style="margin-left: 0px;">Generalizability to other regions or clinical settings may be limited</li>
<li style="margin-left: 0px;">10% non-inferiority margin may be considered relatively wide</li>
</ul>
</div></details>
<details><summary><strong>Clinical Research Relevance</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT dual therapy represents practical alternative to complex quadruple regimens</li>
<li style="margin-left: 0px;">Simpler dosing (2 drugs vs 4 drugs) improves patient compliance</li>
<li style="margin-left: 0px;">Particularly useful for:</li>
<li style="margin-left: 20px;">Patients who struggle with multiple medications</li>
<li style="margin-left: 20px;">Patients who cannot receive amoxicillin due to penicillin allergy</li>
<li style="margin-left: 20px;">Patients who failed previous amoxicillin-containing regimens</li>
</ul>
</div></details>
<details><summary><strong>Basic Research Implications</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Reinforces concept that effective acid suppression + single low-resistance antibiotic achieves reliable eradication</li>
<li style="margin-left: 0px;">Provides mechanistic support for simplified dual therapy strategies</li>
<li style="margin-left: 0px;">Tetracycline maintains low resistance rates (&lt;3%) globally, supporting its use in empiric regimens</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>10. Patient-Facing Summary — Lay Summary</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>What This Study Was About</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">H. pylori is a bacterial infection that can cause stomach problems and increase gastric cancer risk</li>
<li style="margin-left: 0px;">When standard treatments fail (rescue therapy), doctors need simpler, better-tolerated options</li>
<li style="margin-left: 0px;">This study tested a simplified treatment combining only two medications: vonoprazan and tetracycline</li>
</ul>
</div></details>
<details><summary><strong>Who Participated</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">350 adult patients who had failed at least one previous H. pylori treatment</li>
<li style="margin-left: 0px;">Divided into two groups: 175 received VT dual therapy, 175 received standard four-drug therapy</li>
</ul>
</div></details>
<details><summary><strong>What Happened</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Both treatment groups took medications for 14 days</li>
<li style="margin-left: 0px;">VT group: vonoprazan (20 mg twice daily) + tetracycline (500 mg three times daily)</li>
<li style="margin-left: 0px;">BQT group: lansoprazole + bismuth + tetracycline + metronidazole (four drugs)</li>
</ul>
</div></details>
<details><summary><strong>Key Results</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Eradication success</strong>: VT achieved 90.6% eradication vs 89.3% with standard therapy — equally effective</li>
<li style="margin-left: 0px;"><strong>Side effects</strong>: VT caused far fewer adverse events (10.9% vs 45.7%)</li>
<li style="margin-left: 0px;"><strong>Treatment completion</strong>: More patients completed VT therapy (96.0% vs 87.4%)</li>
<li style="margin-left: 0px;">No patients stopped VT due to side effects, but 8.6% stopped standard therapy</li>
</ul>
</div></details>
<details><summary><strong>What This Means for Patients</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">A simpler two-drug treatment works as well as the standard four-drug regimen</li>
<li style="margin-left: 0px;">Fewer side effects makes treatment more comfortable</li>
<li style="margin-left: 0px;">Better completion rates mean more patients achieve successful eradication</li>
<li style="margin-left: 0px;">Particularly helpful for patients allergic to penicillin or who cannot take amoxicillin</li>
</ul>
</div></details>
<details><summary><strong>Bottom Line</strong></summary><div style="padding-left: 20px;">
<p>A simplified treatment combining vonoprazan and tetracycline successfully cleared H. pylori in patients whose previous therapies had failed. It worked as well as standard four-drug regimens but caused fewer side effects, offering a more comfortable option for patients.</p>
</div></details>
</div></details>
<details><summary><strong>11. Funding and Conflicts of Interest</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Funding Sources</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">National High Level Hospital Clinical Research Funding (Youth Clinical Research Project of Peking University First Hospital), 2023YC27</li>
<li style="margin-left: 0px;">Natural Science Foundation of Beijing Municipality, L254077</li>
<li style="margin-left: 0px;">National High Level Hospital Clinical Research Funding (Youth Clinical Research Project of Peking University First Hospital), 2025YC-GD01</li>
</ul>
</div></details>
<details><summary><strong>Conflict of Interest Statement</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Authors declare no competing interests</li>
</ul>
</div></details>
<details><summary><strong>Data Transparency</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Data supporting findings not publicly available due to privacy and ethical restrictions</li>
<li style="margin-left: 0px;">Data available from corresponding author upon reasonable request with institutional review board approval if applicable</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>12. Trial Registration and Ethics</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Registry Information</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Registered at chictr.org.cn (Chinese Clinical Trial Registry)</li>
<li style="margin-left: 0px;">Trial identifier: ChiCTR2400080705</li>
<li style="margin-left: 0px;">Date of registration: February 5th, 2024</li>
</ul>
</div></details>
<details><summary><strong>Ethics Approval</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Study protocol approved by Ethics Committee of Peking University First Hospital</li>
<li style="margin-left: 0px;">Conducted in accordance with ethical principles of the Declaration of Helsinki</li>
</ul>
</div></details>
<details><summary><strong>Informed Consent</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Written informed consent obtained from all participants before enrollment</li>
</ul>
</div></details>
<details><summary><strong>Study Conduct</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Followed CONSORT guidelines for randomized controlled studies</li>
<li style="margin-left: 0px;">Open-label design with blinding of technicians conducting 13C-urea breath tests</li>
</ul>
</div></details>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
